{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"98.5"},{"groupId":"OG001","spread":"0.9","value":"98.7"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"91.0"},{"groupId":"OG001","spread":"0.8","value":"92.2"}]}],"title":"4 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"98.7"},{"groupId":"OG001","spread":"0.8","value":"95.6"}]}],"title":"10-11 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.8","value":"101.5"},{"groupId":"OG001","spread":"0.9","value":"99.9"}]}],"title":"8 Months"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"99.7"},{"groupId":"OG001","spread":"0.9","value":"102.1"}]}],"title":"14 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"277"}],"units":"Participants"}],"description":"Patient reported quality of life as measured with the Treatment Outcome Index of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Endometrium Cancer subscale (16 items). Each item in the FACT-En TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The FACT-En TOI score is calculated as the sum of the subscale scores if more than 80% of the FACT-En TOI items provide valid answers and all of the component subscales have valid scores. The FACT-En TOI score ranges 0-120 with a large score suggests better QOL","dispersionType":"Standard Error","groups":[{"description":"Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.\n\n3-Dimensional Conformal Radiation Therapy: Undergo pelvic radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo pelvic radiation therapy\n\nInternal Radiation Therapy: Undergo vaginal cuff brachytherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Arm I (Pelvic Radiation Therapy)"},{"description":"Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nInternal Radiation Therapy: Undergo vaginal cuff brachytherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Arm II (Brachytherapy, Paclitaxel, Carboplatin)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Provided baseline and \\>= follow-up assessments","reportingStatus":"POSTED","timeFrame":"Prior to study treatment (baseline), 4 weeks post the starting of study treatment, 10-11 weeks post the starting of study treatment, 8 months post the starting of study treatment, 14 months post the starting of study treatment","title":"Patient-reported Quality of Life","type":"SECONDARY","unitOfMeasure":"units on a scale"}